Liquid Biopsy Market Overview

The Liquid Biopsy is anticipated to grow significantly from 2025 to 2035, driven by rapid advancements in cancer diagnostics and non-invasive testing technologies. By 2025, the market is projected to reach a value of around US$ 11.7 Billion. Looking ahead to 2035, it is expected to expand further to about US$ 63.2 Billion. This represents an annual growth rate of 21.8% over the ten-year period.

Liquid biopsy is a revolutionary diagnostic technology that identifies cancer-linked genetic mutations and markers with a single blood test, without the need for surgical or invasive procedures. The novel technique finds growing acceptance in healthcare systems globally owing to its high precision, ability to identify cancer at the earliest stages, and the capability to observe tumor behavior in real time. One of the major drivers of the market growth includes the growing acceptance of liquid biopsies in the field of oncology, including lung, breast cancer, prostate cancer, and colorectal cancer.

Furthermore, advancements in next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis have made the test of liquid biopsy more sensitive and specific. Such factors are boosting the development of the market and prompting healthcare providers and diagnostic firms to invest in research and development and widen the market scope. Also, the market finds support from a global shift in the pattern of clinical practices towards precision medicine and targeted therapies, with the latter strongly dependent upon the genomics of tumors. Liquid biopsy finds applications in the selection of therapy, disease monitoring, and the evaluation of resistance to therapy.

Liquid Biopsy Market Drivers and Opportunities

Rising prevalence of cancer worldwide is anticipated to lift the liquid biopsy market during the forecast period

​The growing worldwide burden of cancer ranks as a major driving force boosting the growth of the market for liquid biopsies. According to the World Health Organization (WHO), cancer continues to be a significant cause of mortality across the world, accounting for about 10 million fatalities each year. Conventional methods of biopsy, though superior, are invasive, painful, and in many instances not possible for repeated sampling. Liquid biopsies offer a non-invasive option that allows real-time tracking and precursory cancer detection of different cancers through straightforward blood tests.

Early cancer detection and screening demand is on the rise, especially in aging populations and amongst high-risk individuals. Detection of circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) by liquid biopsy enables understanding of tumor development, genetic mutations, and responses to treatment. Detection of cancer at the earliest possible stage, often before symptoms arise, by the technology showcased in the market is of immense importance in enhancing survival. Further, the growing awareness of routine health checks increases the number of individuals resorting to preventive diagnostic assessments, further fueling the market size. Trends predict that with the advancements in molecular diagnostic and next-generation sequencing (NGS), the usage of liquid biopsies will enhance drastically in the near future, particularly in the more developed parts of the world with a sophisticated healthcare setup.

Growing adoption of personalized medicine is a vital driver for influencing the growth of the global liquid biopsy market

The increase in personalized medicine is another key driver shaping the growth of the market for liquid biopsy. Personalized or precision medicine takes into account an individual's genetic makeup, lifestyle, and disease-specific characteristics in tailoring the course of action. Liquid biopsy takes center stage in such applications by providing real-time examination of genetic mutations and tumor evolution without the repetition of invasive tissue biopsies. With cancer treatments growing increasingly targeted, the urgency to dynamically observe patient response has never been stronger.

Liquid biopsy allows for such observation by being able to identify the smallest levels of tumor-associated substances in blood or other fluids, enabling clinicians to rapidly adjust therapy. Integration of liquid biopsy in therapeutic regimens maximizes therapeutic benefit and minimizes the possibility of off-target effects by helping patients receive the most likely to benefit from drugs. Pharmaceutical firms and diagnostic developers increasingly collaborate to include the use of liquid biopsy data in drug development and drug trials. Such a development indicates a paradigm shift in oncology toward more responsive and individualized medicine. Such a market, the market for liquid biopsy, is poised to grow strongly as it becomes a key tool in oncology precision medicine pipelines.

Expansion into early cancer screening and minimal residual disease (MRD) detection is poised to create significant opportunities in the global liquid biopsy market

Liquid biopsy is in increasing focus for its potential in earlier cancer screening and minimal residual disease (MRD) identification, and it presents a huge market opportunity. Early cancer identification increases the likelihood of successful treatment and survival. Liquid biopsy enables the identification of genetic and epigenetic alterations in the blood, and allows for non-invasive and routine surveillance. Early results from research indicate high promise for the usage of liquid biopsies for the identification of lung, colorectal, and breast cancers at earlier stages when patients remain asymptomatic. Additionally, the identification of MRD presents a key vertical of applications.

Although after therapy, residual cancer cells in very small quantities remain in the body and result in relapses, these cannot be picked up by traditional imaging and pathology methods. With liquid biopsy, it becomes possible to identify MRD sensitively, and to take preventive action and make informed decisions towards post-treatment management. Increased investments in preventive healthcare and screening programs from regulatory bodies and healthcare organizations will fuel the commercial potential of the market in the solution of cancer detection at an early stage. With increasing validation and proof of its concept in the clinic, liquid biopsy has the promise of becoming a common screening tool, particularly in the case of high-risk subjects, and hence reaching a larger market size and augmenting its growth rate projections.

Liquid Biopsy Market Scope

Liquid Biopsy Market Report Segmentation Analysis

The Global Liquid Biopsy Market Industry Analysis Is Segmented Into By Product, By Technology, By Biomarker, By Application, By End-Use, And By Region.

The instruments segment is anticipated to hold the highest share of the global liquid biopsy market during the projected timeframe

Based on product, the market is segmented into Instruments, Consumables Kits and Reagents, and Software and Services. In 2025, the Instruments segment will have the largest market share of 45.3% in global liquid biopsy market in the forecast period. This is credited to the increasing use of sophisticated instruments like digital PCR systems and next-generation sequencers in research facilities, diagnostic laboratories, and hospitals. Such instruments play a critical role in the quantitation and identification of circulating tumor markers in blood samples. With the increasing need for precision in diagnostics, predominantly in the oncology domain, the need for high-throughput and sensitive instruments also increases.

The multi-gene-parallel analysis (NGS) segment is anticipated to hold the highest share of the market over the forecast period

Based on technology, the market is segmented into Multi-gene-parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays). The Multi-gene-parallel Analysis (NGS) segment will account for the major market share in the long term. NGS technology allows for the simultaneous examination of numerous gene mutations from a single blood test, providing in-depth genomic profiling that is essential for precision medicine.

The circulating nucleic acids segment dominated the market in 2024 and is predicted to grow at the highest CAGR over the forecast period

On the basis of biomarker, the market has been divided into Circulating Tumor Cells (CTCs), Circulating Nucleic Acids, Exosomes/Microvesicles, and Circulating Proteins. The market was dominated by the Circulating Nucleic Acids segment in 2024 and it is expected to achieve the highest CAGR in the forecast period. This is due to the growing utilization of circulating tumor DNA (ctDNA) and RNA for the detection of cancer at an early stage, the monitoring of treatments, and the surveillance of recurrences. Circulating nucleic acids have high specificity and sensitivity and help in the non-invasive examination of the genetics of the tumor without the necessity of a tissue biopsy.

The oncology segment is predicted to grow at the highest CAGR over the forecast period

Based on application, the market is segmented into Non-invasive Prenatal Testing (NIPT), Oncology, and Others. The Oncology segment is predicted to grow at the highest CAGR over the forecast period. Liquid biopsy is revolutionizing cancer diagnostics by offering a less invasive alternative to tissue biopsies, allowing for real-time monitoring of tumor dynamics. The ability to detect early-stage cancers, identify actionable mutations, and assess treatment response has made liquid biopsy an integral part of personalized oncology care.

The hospitals and laboratories segment is expected to dominate the market during the forecast period.

Based on end-use, the market is segmented into Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and Others. The Hospitals and Laboratories segment is expected to dominate the market during the forecast period. This is due to the widespread integration of liquid biopsy technologies in hospital diagnostics and central laboratories for cancer detection and genetic testing. Hospitals and diagnostic labs often serve as primary points of care, especially for cancer patients, leading to higher test volumes and faster adoption of new diagnostic technologies.

The following segments are part of an in-depth analysis of the global liquid biopsy market:

Liquid Biopsy Market Share Analysis by Region

North America is projected to hold the largest share of the global liquid biopsy market over the forecast period.

North America held the most significant market share in the global market, with about 49.5% of the market in 2024, and will continue to enjoy its leadership over the forecasting period. The region's high level of healthcare development, high concentration of the world's top developers of liquid biopsy tests, and high awareness of the importance of cancer early detection and personalized medicine contribute to the region sharing such a high market position. The region's high rate of utilization of precision diagnostic applications and positive reimbursement policies also contribute to the increasing demand.

The high rate of R&D activities in the region, along with the high rate of collaboration between academic centers, biotechnology companies, and healthcare organizations, contribute to the high growth rate and quick commercialization of new liquid biopsy technologies. Regulatory agencies such as the FDA also facilitated the speedy approval of new tests, enabling wide-scale clinical use. Furthermore, the high incidence of cancer and rising aging of the population contribute to high demand in the region for non-invasive and efficient diagnosis techniques. Availability of sophisticated diagnostic hardware, high per capita healthcare spending, and high government funding to support R&D activities also contribute to the dominance of North America in the global market for liquid biospy.

Meanwhile, the Asia-Pacific region is projected to witness the highest CAGR during the forecast period, driven by expanding healthcare access, increasing awareness of early cancer screening, and a growing patient pool. Countries like China, India, and Japan are investing significantly in healthcare infrastructure, which is expected to boost market growth in the region.

Liquid Biopsy Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range of Liquid Biopsy products. Some of the key players include Bio-Rad Laboratories, Inc., Epic Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Inc., and Others.

Global Liquid Biopsy Market Recent Developments News:

In February 2024, Myriad Genetics, Inc. (US) has signed a definitive agreement to acquire key assets from Intermountain Health, including its Precision Genomics (IPG) laboratory business. The acquisition encompasses IPG's proprietary diagnostic tests—the Precise Tumor Test and Precise Liquid Test—along with its CLIA-certified laboratory. This strategic move strengthens Myriad's oncology portfolio and expands its capabilities in precision medicine, enhancing its position in advanced genomic testing. The deal underscores Myriad's commitment to delivering comprehensive, cutting-edge diagnostic solutions for improved cancer care.

In November 2023, Illumina Inc. has launched the TruSight Oncology 500 ctDNA v2, an advanced liquid biopsy assay designed to enhance genomic profiling of cancer. This next-generation solution enables high-sensitivity detection of circulating tumor DNA (ctDNA), empowering clinicians with comprehensive, non-invasive insights into tumor genomics. The assay supports precision oncology by identifying actionable mutations and biomarkers to guide personalized treatment decisions.

The Global Liquid Biopsy Market is dominated by a few large companies, such as

·         Bio-Rad Laboratories, Inc. 

·         Epic Sciences 

·         Exact Sciences Corporation 

·         F. Hoffmann-La Roche Ltd 

·         Guardant Health 

·         Illumina, Inc. 

·         Johnson & Johnson Services, Inc. 

·         Labcorp 

·         mdxhealth 

·         Menarini Silicon Biosystems 

·         Natera, Inc. 

·         NeoGenomics Laboratories 

·         Oncocyte Corporation 

·         PathAI, Inc. 

·         QIAGEN 

·         Sysmex Inostics Inc. 

·         Thermo Fisher Scientific Inc. 

·         Others